Kiniksa Pharmaceuticals International, plc - Common Stock (KNSA) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2024 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
KNSA on Nasdaq
Shares outstanding
43,510,440
Price per share
$41.25
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
40,800,729
Total reported value
$1,584,103,697
% of total 13F portfolios
0%
Share change
+807,561
Value change
+$42,759,189
Number of holders
199
Price from insider filings
$41.25
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Kiniksa Pharmaceuticals International, plc - Common Stock (KNSA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Rubric Capital Management LP 9.2% +15% $108,181,595 +$14,569,740 3,909,806 +16% RUBRIC CAPITAL MANAGEMENT LP 30 Jun 2025
VANGUARD GROUP INC 7% $118,941,532 3,063,135 The Vanguard Group 30 Sep 2025
TANG CAPITAL MANAGEMENT LLC 5.2% $46,556,874 2,178,609 TANG CAPITAL MANAGEMENT, LLC 28 Mar 2025
BlackRock, Inc. 1% -88% $11,570,238 -$51,021,128 418,151 -82% BlackRock, Inc. 30 Jun 2025

As of 30 Sep 2025, 199 institutional investors reported holding 40,800,729 shares of Kiniksa Pharmaceuticals International, plc - Common Stock (KNSA). This represents 94% of the company’s total 43,510,440 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Kiniksa Pharmaceuticals International, plc - Common Stock (KNSA) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Rubric Capital Management LP 9.2% 4,000,000 +2.3% 2.1% $155,320,000
VANGUARD GROUP INC 7% 3,063,135 -2.2% 0% $118,941,532
BAKER BROS. ADVISORS LP 6.5% 2,824,669 0% 0.79% $109,681,897
TANG CAPITAL MANAGEMENT LLC 5.4% 2,328,609 0% 3.5% $90,419,887
Fairmount Funds Management LLC 4.1% 1,772,839 0% 6.2% $68,839,338
ACADIAN ASSET MANAGEMENT LLC 3.7% 1,618,521 +28% 0.11% $62,824,000
MORGAN STANLEY 3.1% 1,362,922 +28% 0% $52,922,261
D. E. Shaw & Co., Inc. 2.6% 1,134,186 +43% 0.04% $44,040,443
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 2.5% 1,068,263 +45% 0.03% $41,480,652
MILLENNIUM MANAGEMENT LLC 2.3% 1,014,125 -0.57% 0.03% $39,378,474
Pictet Asset Management Holding SA 2.1% 932,096 -5.3% 0.03% $36,193,288
FMR LLC 1.8% 799,755 -0.89% 0% $31,054,496
Connor, Clark & Lunn Investment Management Ltd. 1.7% 725,355 +16% 0.09% $28,165,535
Qube Research & Technologies Ltd 1.6% 689,888 -22% 0.04% $26,788,351
Parkman Healthcare Partners LLC 1.5% 671,592 +37% 2.9% $26,077,917
Driehaus Capital Management LLC 1.5% 654,585 +1% 0.18% $25,417,536
BNP PARIBAS FINANCIAL MARKETS 1.5% 653,411 0% 0.02% $25,371,949
BRAIDWELL LP 1.5% 643,180 -42% 0.74% $24,974,679
DIMENSIONAL FUND ADVISORS LP 1.5% 632,123 -2.5% 0.01% $24,545,132
RICE HALL JAMES & ASSOCIATES, LLC 1.3% 577,822 -9.5% 1.2% $22,436,828
Point72 Asset Management, L.P. 1.3% 566,927 -33% 0.05% $22,013,743
GOLDMAN SACHS GROUP INC 1.3% 546,510 +42% 0% $21,220,983
DEUTSCHE BANK AG\ 1.2% 533,375 +44% 0.01% $20,710,951
BANK OF AMERICA CORP /DE/ 1.1% 495,483 +82% 0% $19,239,604
TWO SIGMA INVESTMENTS, LP 1.1% 461,770 +182% 0.03% $17,930,529

Institutional Holders of Kiniksa Pharmaceuticals International, plc - Common Stock (KNSA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,757,788 $72,506,096 +$22,441,913 $41.25 21
2025 Q3 40,800,729 $1,584,103,697 +$42,759,189 $38.83 199
2025 Q2 39,765,765 $1,100,293,484 +$3,474,538 $27.67 186
2025 Q1 39,936,950 $887,052,494 +$25,344,007 $22.21 173
2024 Q4 38,910,834 $769,756,202 -$20,642,445 $19.78 156
2024 Q3 39,503,444 $987,347,556 +$124,891,730 $24.99 172
2024 Q2 35,248,812 $658,014,093 +$655,780,340 $18.67 126